Back to Peptides

Pancragen

Moderate Research

KEDW Tetrapeptide | Pancreas Bioregulator

Dose 10-20mg daily
Frequency Daily for 10-20 days per cycle
Cycle 10-20 days
Storage Capsules at room temperature; reconstituted injectable at 2-8°C refrigerated

Pancragen is a Khavinson bioregulator tetrapeptide (KEDW) originally isolated from bovine pancreatic cells. Developed at Russia's St. Petersburg Institute of Bioregulation and Gerontology, it directly interacts with DNA to regulate pancreatic gene expression. Research in old rhesus monkeys demonstrated that Pancragen corrected impaired glucose tolerance, normalized insulin and C-peptide levels, and improved endocrine pancreatic function. It is considered safe and effective for age-related metabolic disturbances.

Mechanism of Action

Pancragen works through epigenetic regulation by interacting with chromatin complexes and DNA structures to modulate pancreatic gene expression. Research shows it upregulates critical transcription factors for pancreatic cell maturation including Pdx1, Pax6, Ptf1a, Foxa2, Nkx2.2, and Pax4. Its small size (4 amino acids, ~576 Da) allows it to traverse cellular membranes and interact with nuclear components including histones and DNA.

Key Benefits

  • Corrects impaired glucose tolerance
  • Normalizes insulin levels
  • Normalizes C-peptide levels
  • Improves endocrine pancreatic function
  • Supports pancreatic cell differentiation
  • Regulates melatonin expression
  • Reduces metabolic syndrome incidence
  • Upregulates key pancreatic transcription factors
Molecular Weight
576 Da
Chain Length
4 amino acids
Type
Tetrapeptide bioregulator
Amino Acid Sequence
One-letter: KEDW
H₂N
K 1
O ‖ C
N
E 2
O ‖ C
N
D 3
O ‖ C
N
W 4
COOH
Lys
1

Lysine

Position 1

Glu
2

Glutamic Acid

Position 2

Asp
3

Aspartic Acid

Position 3

Trp
4

Tryptophan

Position 4

N-terminus C-terminus
Hydrophobic
Polar
Positive (+)
Negative (-)
Modified

Metabolic Support

  • Impaired Glucose Tolerance

    Corrects age-related glucose tolerance disturbances in primate studies.

  • Metabolic Syndrome

    Reduces incidence and magnitude of metabolic syndrome.

  • Blood Sugar Regulation

    Helps control blood sugar through pancreatic function support.

Pancreatic Health

  • Pancreatic Cell Differentiation

    Impacts differentiation of pancreatic cells during aging.

  • Endocrine Function

    Improves endocrine function of the pancreas.

  • Age-Related Pancreatic Decline

    Addresses age-related imbalance of pancreatic function.

Anti-Aging

  • Gene Expression Regulation

    Directly interacts with DNA to regulate pancreatic gene expression.

Available in capsule form for oral administration. Short peptides can be absorbed orally and reach target tissues. Typical protocol involves 10-20 day cycles.

GoalDoseFrequencyRoute
Standard protocol10-20 mgDaily for 10-20 daysOral capsules
Maintenance10 mg2-3 cycles yearlyOral capsules
Epitalon

Often combined in comprehensive anti-aging Khavinson protocols.

synergistic
Livagen

Different organ targets; can be used in comprehensive bioregulator protocols.

compatible
Vilon

Part of Khavinson bioregulator family; targets different tissue.

compatible
GLP-1 agonists

Both affect glucose metabolism; interaction unknown.

unknown
During cycle

Gene expression modulation begins

Post-cycle

Effects persist due to epigenetic changes

Weeks-Months

Glucose tolerance and pancreatic function improvements

Long-term

Cumulative benefits with periodic cycles

Common Side Effects

  • Generally well-tolerated
  • Minimal side effects reported

Stop Signs - Discontinue if:

  • Allergic reactions
  • Unusual blood sugar changes
  • Signs of hypoglycemia

Contraindications

  • Active pancreatic emergencies (seek medical care)
  • Known hypersensitivity
  • Pregnancy or breastfeeding
  • Type 1 diabetes (consult physician)

Good Signs

  • White powder or capsules
  • Clear solution if reconstituted
  • Proper packaging and labeling

Warning Signs

  • Unknown source or purity

Bad Signs

  • Discoloration
  • Unusual odor
  • Damaged packaging
  • Correction of Impaired Glucose Tolerance Using Tetrapeptide (Pancragen) in Old Female Rhesus Monkeys
    PubMed (2017)

    Pancragen normalized insulin and C-peptide levels, suggesting recovery of disturbed glucose tolerance in old animals.

  • Tetrapeptide KEDW Interacts with DNA and Regulates Gene Expression
    Bulletin of Experimental Biology and Medicine (2015)

    KEDW directly interacts with DNA and regulates pancreatic gene expression.

  • Impacts of Pancragen on Differentiation of Pancreatic Cells During Aging
    Bulletin of Experimental Biology and Medicine (2013)

    Pancragen affects pancreatic cell differentiation during aging process.

  • Prospects of Using Pancragen for Metabolic Disorders in Elderly
    Bulletin of Experimental Biology and Medicine (2011)

    Pancragen shows promise for correction of metabolic disorders in elderly people.

Disclaimer

This information is for educational and research purposes only. Consult a healthcare professional before use.